Kenilworth-based Merck announced Tuesday it intends to consolidate its New Jersey campuses into a single location in Rahway.
In its first quarter 2020 financial results, the company said that Rahway, the birthplace of life-changing scientific breakthroughs that have improved human health over the last century, would once again be Merck’s global headquarters by the end of 2023.
“We remain committed to New Jersey and invested in the state as the home of our global headquarters,” the report reads.
Merck reported in Q1, worldwide sales were $12.1 billion – an increase of 11 percent.
Due to the impact of COVID-19, the company lowered its 2020 full-year revenue range to be between $46.1 billion and $48.1 Billion.
Merck said it is active in COVID-19-related antiviral and vaccine research.
“In this challenging and unprecedented time, the quality of our first-quarter performance reflects strong demand for our portfolio of innovative products, continued commercial and clinical execution and the dedication and resilience of our employees around the world. The fundamentals of our business remain strong,” said Kenneth Frazier, chairman and chief executive officer, who was announced as co-chair of Gov. Phil Murphy’s Restart and Recovery Commission, a component of his The Road Back plan to restart and reopen the state’s economy.
“The COVID-19 global pandemic poses challenges to all of us, including serious threats to the health of people, businesses and economies around the world. Without question, our industry and our company have a unique ability and responsibility to help the world respond to this pandemic by working collaboratively to deliver solutions to coronavirus infection while also maintaining the supply of medically important products to those who need them,” said Frazier.